Transmembrane TNF-A Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2

Journal of Immunology

Volumn 192, Issue 3, 2014, Pages 1320-1331

  Hu, Xin ^a   Li, Baihua ^a   Li, Xiaoyan ^a   Zhao, Xianxian ^a   Wan, Lin ^a   Lin, Guohong ^a   Yu, Min ^a   Wang, Jing ^a   Jiang, Xiaodan ^a   Feng, Wei ^a   Qin, Zhihai ^b   Yin, Bingjiao ^a   Li, Zhuoya ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; SECRETORY TUMOR NECROSIS FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRANSMEMBRANE TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; ARG1 PROTEIN, MOUSE; ARGINASE; HYBRID PROTEIN; NOS2 PROTEIN, MOUSE; TNFRSF1A PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER LOCALIZATION; CELL ACTIVATION; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; GENETIC TRANSCRIPTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SUPPRESSOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW CELL; ENZYME INDUCTION; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLUBILITY; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ARGINASE; BASE SEQUENCE; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MYELOID CELLS; NEOPLASM PROTEINS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84893381289     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203195     Document Type: Article

References (56)

1. Chen, H., L. Xiao, H. Zhang, N. Liu, T. Liu, L. Liu, X. Hu, D. Yan, K. Yang, B. Yin, et al. 2011. The involvement of b-Actin in the signaling of transmembrane TNF-A-mediated cytotoxicity. J. Leukoc. Biol. 89: 917-926.
2. Li, Q., L. Li, W. Shi, X. Jiang, Y. Xu, F. Gong, M. Zhou, C. K. Edwards, III, and Z. Li. 2006. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-Alpha in vitro and in vivo. Cancer Immunol. Immunother. 55: 1470-1479.
3. Szlosarek, P. W., and F. R. Balkwill. 2003. Tumour necrosis factor a: a potential target for the therapy of solid tumours. Lancet Oncol. 4: 565-573.
4. Moore, R. J., D. M. Owens, G. Stamp, C. Arnott, F. Burke, N. East, H. Holdsworth, L. Turner, B. Rollins, M. Pasparakis, et al. 1999. Mice deficient in tumor necrosis factor-A are resistant to skin carcinogenesis. Nat. Med. 5: 828-831.
5. Balkwill, F. 2006. TNF-A in promotion and progression of cancer. Cancer Metastasis Rev. 25: 409-416.
6. Popivanova, B. K., K. Kitamura, Y. Wu, T. Kondo, T. Kagaya, S. Kaneko, M. Oshima, C. Fujii, and N. Mukaida. 2008. Blocking TNF-A in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118: 560-570.
7. Egberts, J. H., V. Cloosters, A. Noack, B. Schniewind, L. Thon, S. Klose, B. Kettler, C. von Forstner, C. Kneitz, J. Tepel, et al. 2008. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 68: 1443-1450.
8. Qin, Z., S. Kruger-Krasagakes, U. Kunzendorf, H. Hock, T. Diamantstein, and T. Blankenstein. 1993. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp. Med. 178: 355-360.
9. Yan, D., N. Qin, H. Zhang, T. Liu, M. Yu, X. Jiang, W. Feng, J. Wang, B. Yin, T. Zhang, et al. 2009. Expression of TNF-A leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-A. Breast Cancer Res. Treat. 116: 91-102.
10. Zhang, H., D. Yan, X. Shi, H. Liang, Y. Pang, N. Qin, H. Chen, J. Wang, B. Yin, X. Jiang, et al. 2008. Transmembrane TNF-A mediates "forward" and "reverse" signaling, inducing cell death or survival via the NF-kB pathway in Raji Burkitt lymphoma cells. J. Leukoc. Biol. 84: 789-797.
11. Chen, X., M. Baumel, D. N. Mannel, O. M. Howard, and J. J. Oppenheim. 2007. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 179: 154-161.
12. Kleijwegt, F. S., S. Laban, G. Duinkerken, A. M. Joosten, A. Zaldumbide, T. Nikolic, and B. O. Roep. 2010. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J. Immunol. 185: 1412-1418.
13. Grell, M., E. Douni, H. Wajant, M. Lohden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, and P. Scheurich. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802.
14. Kneilling, M., R. Mailhammer, L. Hultner, T. Schonberger, K. Fuchs, M. Schaller, D. Bukala, S. Massberg, C. A. Sander, H. Braumuller, et al. 2009. Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood 114: 1696-1706.
15. Mazzon, E., E. Esposito, R. Di Paola, C. Muia, C. Crisafulli, T. Genovese, R. Caminiti, R. Meli, P. Bramanti, and S. Cuzzocrea. 2008. Effect of tumour necrosis factor-A receptor 1 genetic deletion on carrageenan-induced acute inflammation: a comparison with etanercept. Clin. Exp. Immunol. 153: 136-149.
16. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
17. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182: 4499-4506.
18. Sonda, N., M. Chioda, S. Zilio, F. Simonato, and V. Bronte. 2011. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr. Opin. Immunol. 23: 279-285.
19. Gabrilovich, D., T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, and D. P. Carbone. 1998. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92: 4150-4166.
20. Pan, P. Y., G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S. H. Chen. 2008. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111: 219-228.
21. Serafini, P., R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello. 2004. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64: 6337-6343.
22. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
23. Bunt, S. K., L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67: 10019-10026.
24. Sinha, P., V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507-4513.
25. Sinha, P., C. Okoro, D. Foell, H. H. Freeze, S. Ostrand-Rosenberg, and G. Srikrishna. 2008. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181: 4666-4675.
26. Zhao, X., L. Rong, X. Zhao, X. Li, X. Liu, J. Deng, H. Wu, X. Xu, U. Erben, P. Wu, et al. 2012. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122: 4094-4104.
27. Hahnfeldt, P., D. Panigrahy, J. Folkman, and L. Hlatky. 1999. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59: 4770-4775.
28. Kusmartsev, S. A., Y. Li, and S. H. Chen. 2000. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165: 779-785.
29. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 22DDC(T) method. Methods 25: 402-408.
30. Liu, D., J. Yu, H. Chen, R. Reichman, H. Wu, and X. Jin. 2006. Statistical determination of threshold for cellular division in the CFSE-labeling assay. J. Immunol. Methods 312: 126-136.
31. Decoster, E., B. Vanhaesebroeck, P. Vandenabeele, J. Grooten, and W. Fiers. 1995. Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J. Biol. Chem. 270: 18473-18478.
32. Delano, M. J., P. O. Scumpia, J. S. Weinstein, D. Coco, S. Nagaraj, K. M. Kelly-Scumpia, K. A. O'Malley, J. L. Wynn, S. Antonenko, S. Z. Al-Quran, et al. 2007. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204: 1463-1474.
33. Tu, S., G. Bhagat, G. Cui, S. Takaishi, E. A. Kurt-Jones, B. Rickman, K. S. Betz, M. Penz-Oesterreicher, O. Bjorkdahl, J. G. Fox, and T. C. Wang. 2008. Overexpression of interleukin-1b induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14: 408-419.
34. Wajant, H., and P. Scheurich. 2011. TNFR1-induced activation of the classical NF-kB pathway. FEBS J. 278: 862-876.
35. Beyaert, R., A. Cuenda, W. Vanden Berghe, S. Plaisance, J. C. Lee, G. Haegeman, P. Cohen, and W. Fiers. 1996. The p38/RK mitogen-Activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 15: 1914-1923.
36. Westwick, J. K., C. Weitzel, A. Minden, M. Karin, and D. A. Brenner. 1994. Tumor necrosis factor a stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J. Biol. Chem. 269: 26396-26401.
37. Yu, H. N., Y. R. Lee, E. M. Noh, K. S. Lee, E. K. Song, M. K. Han, Y. C. Lee, C. Y. Yim, J. Park, B. S. Kim, et al. 2008. Tumor necrosis factor-A enhances DMSO-induced differentiation of HL-60 cells through the activation of ERK/MAPK pathway. Int. J. Hematol. 87: 189-194.
38. Yang, L., L. M. DeBusk, K. Fukuda, B. Fingleton, B. Green-Jarvis, Y. Shyr, L. M. Matrisian, D. P. Carbone, and P. C. Lin. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
39. Huang, B., P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S. H. Chen. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumorbearing host. Cancer Res. 66: 1123-1131.
40. Song, X., Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte. 2005. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1b-secreting cells. J. Immunol. 175: 8200-8208.
41. Cheng, P., C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.
42. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.
43. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
44. Hamid, T., Y. Gu, R. V. Ortines, C. Bhattacharya, G. Wang, Y. T. Xuan, and S. D. Prabhu. 2009. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kB and inflammatory activation. Circulation 119: 1386-1397.
45. Suvannavejh, G. C., H. O. Lee, J. Padilla, M. C. Dal Canto, T. A. Barrett, and S. D. Miller. 2000. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG35-55-induced experimental autoimmune encephalomyelitis. Cell. Immunol. 205: 24-33.
46. Chen, X., and J. J. Oppenheim. 2010. TNF-A: an activator of CD4+FoxP3+ TNFR2+ regulatory T cells. Curr. Dir. Autoimmun. 11: 119-134.
47. Saha, R. N., M. Jana, and K. Pahan. 2007. MAPK p38 regulates transcriptional activity of NF-kB in primary human astrocytes via acetylation of p65. J. Immunol. 179: 7101-7109.
48. Vanden Berghe, W., S. Plaisance, E. Boone, K. De Bosscher, M. L. Schmitz, W. Fiers, and G. Haegeman. 1998. p38 And extracellular signal-regulated kinase mitogen-Activated protein kinase pathways are required for nuclear factor-kB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273: 3285-3290.
49. Marr, R. A., C. L. Addison, D. Snider, W. J. Muller, J. Gauldie, and F. L. Graham. 1997. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. 4: 1181-1188.
50. Holler, R. A., K. Song, N. Fan, and D. J. Chang. 1992. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70: 47-56.
51. Hanson, E. M., V. K. Clements, P. Sinha, D. Ilkovitch, and S. Ostrand-Rosenberg. 2009. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183: 937-944.
52. Yang, R., Z. Cai, Y. Zhang, W. H. Yutzy, IV, K. F. Roby, and R. B. Roden. 2006. CD80 in immune suppression by mouse ovarian carcinoma-Associated Gr-1+ CD11b+ myeloid cells. Cancer Res. 66: 6807-6815.
53. Yang, L., J. Huang, X. Ren, A. E. Gorska, A. Chytil, M. Aakre, D. P. Carbone, L. M. Matrisian, A. Richmond, P. C. Lin, and H. L. Moses. 2008. Abrogation of TGFb signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
54. Clauss, M., C. Sunderkotter, B. Sveinbjornsson, S. Hippenstiel, A. Willuweit, M. Marino, E. Haas, R. Seljelid, P. Scheurich, N. Suttorp, et al. 2001. A permissive role for tumor necrosis factor in vascular endothelial growth factorinduced vascular permeability. Blood 97: 1321-1329.
55. Rajashekhar, G., A. Willuweit, C. E. Patterson, P. Sun, A. Hilbig, G. Breier, A. Helisch, and M. Clauss. 2006. Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. J. Vasc. Res. 43: 193-204.
56. Yu, M., X. Zhou, L. Niu, G. Lin, J. Huang, W. Zhou, H. Gan, J. Wang, X. Jiang, B. Yin, and Z. Li. 2013. Targeting transmembrane TNF-A suppresses breast cancer growth. Cancer Res. 73: 4061-4074.